Who are Org 5730's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Trisenox, Sparcin, Alimix, Orlaam, Hismanal, Seldane.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/bepridil.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

Org 5730 — Competitive Intelligence Brief

Org 5730 (BEPRIDIL) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: High Risk QT Prolonging Agents. Area: Cardiovascular.

marketed High Risk QT Prolonging Agents Voltage-dependent P/Q-type calcium channel subunit alpha-1A Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

Org 5730 (BEPRIDIL).

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Org 5730 TARGET	BEPRIDIL		marketed	High Risk QT Prolonging Agents	Voltage-dependent P/Q-type calcium channel subunit alpha-1A	1990-01-01
Trisenox	ARSENIC TRIOXIDE	Cephalon	marketed	High Risk QT Prolonging Agents	Potassium voltage-gated channel subfamily H member 2	2000-01-01
Sparcin	SPARFLOXACIN		marketed	High Risk QT Prolonging Agents	Potassium voltage-gated channel subfamily H member 2	1996-01-01
Alimix	CISAPRIDE		marketed	High Risk QT Prolonging Agents	5-hydroxytryptamine receptor 2A	1993-01-01
Orlaam	LEVOMETHADYL ACETATE	Roxane	marketed	High Risk QT Prolonging Agents	Potassium voltage-gated channel subfamily H member 2	1993-01-01
Hismanal	ASTEMIZOLE		marketed	High Risk QT Prolonging Agents	Potassium voltage-gated channel subfamily H member 2	1988-01-01
Seldane	TERFENADINE		marketed	High Risk QT Prolonging Agents	Histamine H1 receptor	1985-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (High Risk QT Prolonging Agents class)

· 8 drugs in this class
Cephalon · 1 drug in this class
Pfizer · 1 drug in this class
Roxane · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Org 5730 — Competitive Intelligence Brief. https://druglandscape.com/ci/bepridil. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab